Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: A phase II study

International Journal of Gynecological Cancer

Volumn 13, Issue 2, 2003, Pages 130-137

  Bauknecht, Thomas ^a,h   Hefti, A ^b   Morack, G ^c   Villena Heinsen, C ^d   Wallwiener, D ^e   Elling, D ^f   Minckwitz, G V ^g   Mansouri, K ^a   Blatter, J ^a   Breitbach, G P ^b  

^a Eli Lilly GmbH Deutschland   (Germany)

^b Abteilung Innere Medizin Städtisches Krankenhaus   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d Oskar Ziethen Krankenhaus ^*  (Germany)

^e Univerität Frauenklinik   (Germany)

^f MARTIN LUTHER KRANKENHAUS   (Germany)

^g GOETHE UNIVERSITY   (Germany)

^h LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Cisplatin; Gemcitabine; Ovarian cancer

Indexed keywords

CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; AGE; CARCINOMA; DISEASE FREE SURVIVAL; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; SURVIVAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037969850     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13039.x     Document Type: Article

References (26)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
2. Saarland in Figures. Morbidity and Mortality due to malign tumors in Saarland 1993 - Annual Report - Cancer Register Saarland, Special Edition 186, 1996 Statistical State Office Saarland.
3. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
4. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
5. Harper P. A randomized comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 patients randomised into the 3rd International Collaborative Ovarian Neoplasm Study (ICON3). Proc Am Soc Clin Oncol 1999;18:356a (Abstract 1375).
6. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106-15.
7. Hoskins P, Eisenhauer E, Vergote I et al. Phase II feasibility study of sequential doublets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 2000;18:4038-44.
8. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-3.
9. von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999;10:853-5.
10. Friedlander M, Millward MJ, Bell D et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998;9:1343-5.
11. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89-93.
12. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998;25:340-8 (Review).
13. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22 (Suppl. 11):72-9.
14. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-30.
15. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
16. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma; prognostic factors. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th edn, Vol. 2. Philadelphia: Lippincott Williams & Wilkins, 2001:1604.
17. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
18. Piccart MJ, du Bois A, Gore ME et al. A new standard of care for treatment of ovarian cancer. Eur J Cancer 2000;36:10-2.
19. Brenner H, Stegmaier C, Ziegler H. Trends in survival of patients with ovarian cancer in Saarland, Germany, 1976-95. J Cancer Res Clin Oncol 1999;125:109-13.
20. Bertelsen K, Andersen JE. Long-term survival and prognostic factors in advanced epithelial ovarian cancer with special emphasis upon the effect of protocol inclusion. Int J Gynecol Cancer 1994;4:180-7.
21. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer 2001;85:944-52.
22. Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176-82.23.
23. Conte PF, Bruzzone M, Carnino F et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996;14:351-6.
24. Krakowski I, Petit T, Kayitalire L et al. Gemcitabine (Gemzar®) in combination with cisplatin (CP) in advanced ovarian cancers (AOC): a phase II study. Proc Am Soc Clin Oncol 1998;17:356a (Abstract 1373).
25. Nogué M, Cirera L, Arcusa M et al. Gemcitabine combined with cisplatin first line: a phase II study in patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998;17:357a (Abstract 1377).
26. Hansen SW, Anderson H, Boman K et al. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc Am Soc Clin Oncol 1999;18:357a (Abstract 1379).